Effect of Citrulline and Glutamine on Nitric Oxide Production in RAW 264.7 Cells in an Arginine-Depleted Environment

Abstract

Background: Nitric oxide (NO) is a highly reactive free radical essential for antimicrobial and tumor immunity as well as endothelial function. Arginine is a limiting factor in NO synthesis. Citrulline can be converted to arginine and might restore NO production when arginine availability is limited, while glutamine may competitively inhibit citrulline availability. We aimed to assess how these amino acids interact to generate NO using an in vitro model. Methods: RAW 264.7 cells were exposed to various amino acid concentrations before and after lipopolysaccharide (LPS) stimulation, and NO production was assessed. Results: NO production directly correlated up to 200 μM with arginine available after LPS stimulation (R ² = 0.99). Provided the same arginine concentrations following LPS stimulation, low arginine precultured cells produced significantly less NO than high arginine precultured cells (P < .01). Citrulline added to low arginine preculture significantly increased NO production compared to cells in low arginine alone (P < .01). When glutamine was withdrawn before and after LPS stimulation, cells precultured in low arginine and citrulline produced NO equivalent to that of high arginine precultured cells. Additional citrulline provided after LPS stimulation additionally improved NO production beyond that observed in cells precultured in high arginine (P < .01), and NO production became less dependent on arginine availability (R ² = 0.78). Conclusion: Arginine availability is a limiting factor for NO production. Citrulline is a potential substitute to restore NO production when arginine availability is limited. Glutamine appears to be an important modulator that interferes with citrulline-mediated NO production.

Get full access to this article

View all access options for this article.

References

Bogdan C, Rollinghoff M, Diefenbach A. The role of nitric oxide in innate immunity. Immunol Rev. 2000 ;173:17 -26.

Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol.1994 ;266(6 Pt 1):E829 -E839.

Loscalzo J, Welch G. Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis.1995 ;35:87 -104.

Morris SM Jr, Kepka-Lenhart D, Chen LC. Differential regulation of arginases and inducible nitric oxide synthase in murine macrophage cells.Am J Physiol .1998 ;275(5 pt 1):E740 -E747.

Morris SM Jr. Arginine metabolism: boundaries of our knowledge.J Nutr . 2007;137:1602S -1609S.

Gold MEK, Wood KS, Buga RE, Byrnss RE, Ignarro LJ. L-Arginine causes whereas L-arginosuccinic acid inhibits endothelium-dependent vascular smooth muscle relaxation. Biochem Biophys Res Commun.1989 ;161:536 -543.

Palmer, RMJ, Ashton D, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature Lond.1988 ;333:664 -666.

Naseem KM. The role of nitric oxide in cardiovascular diseases.Mol Aspect Med . 2005;26:33 -65.

Munder M, Eichmann K, Moran JM, Centeno F, Soler G, Modolell M. Th1/Th2-regulated expression of arginase isoforms in murine macrophages and dendritic cells. J Immunol.1999 ;163:3771 -3777.

10.

Barksdale AR, Bernard AC, Maley ME, et al. Regulation of arginase expression by T-helper II cytokines and isoproterenol. Surgery.2004 ;135:527 -535.

11.

Braga M, Gianotti L, Radaelli G, et al. Perioperative immunonutrition in patients undergoing cancer surgery: results of a randomized, double-blind, phase 3 trial. Arch Surg.1999 ;134:428 -433.

12.

Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer.Gastroenterology . 2002;122:1763 -1770.

13.

Wilmore D. Enteral and parenteral arginine supplementation to improve medical outcomes in hospitalized patients. J Nutr.2004 ; 134(Suppl 10):S2863 -S2867.

14.

Heyland DK. Nutritional support in the critically ill patients. A critical review of the evidence. Crit Care Clin.1998 ;14:423 -440.

15.

Morris CR, Kato GJ, Poljakovic M, et al. Dysregulated arginine metabolism, hemolysis-associated pulmonary hypertension, and mortality in sickle cell disease. JAMA.2005 ;294:81 -90.

16.

Makarenkova VP, Bansal V, Matta BM, Perez LA, Ochoa JB. CD11b+/Gr-1+ myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol.2006 ;176:2085 -2094.

17.

Popovic PJ, Zeh HJ, Ochoa JB. Arginine and immunity. J Nutr. 2007;137:1681S -1686S.

18.

Sosroseno W, Herminajeng E, Bird PS, Seymour GJ. L-arginine-dependent nitric oxide production of a murine macrophage-like RAW 264.7 cell line stimulated with porphyromonas gingivalis lipopolysaccharide.Oral Microbiol Immunol .2004 ;19:65 -70.

19.

Zhou M, Martindale RG. Arginine in the critical care setting.J Nutr . 2007;137:1687S -1692S.

20.

Morris SM Jr. Enzymes of arginine metabolism. J Nutr. 2004;134:S2473 -S2477.

21.

Wu GY, Brosnan JT. Macrophages can convert citrulline into arginine [published correction appears in Biochem J. 1992;283(pt 3): 919].Biochem J .1992 ;281(pt 1):45 -48.

22.

Mori M, Gotoh T, Nagasaki A, Takiguchi M, Sonoki T. Regulation of the urea cycle enzyme genes in nitric oxide synthesis. J Inherit Metab Dis. 1998;21(Suppl 1): 59-71.

23.

Nussler AK, Billiar TR, Liu ZZ, Morris SM Jr. Coinduction of nitric oxide synthase and argininosuccinate synthetase in a murine macrophage cell line. Implications for regulation of nitric oxide production. J Biol Chem. 1994;269:1257 -1261.

24.

Bellows CF, Jaffe BM. Glutamine is essential for nitric oxide synthesis by murine macrophages. J Surg Res.1999 ;86:213 -219.

25.

Sessa WC, Hecker JM, Mitchell JA, Vane JR. The metabolism of L-arginine and it significance for the biosynthesis of endothelium-derived relaxing factor: L-glutamine inhibits the generation of L-arginine by cultured endothelial cells. Proc Natl Acad Sci.1990 ;87:8607 -8611.

26.

Wu G, Meininger C. Regulation of L-arginine synthesis from L-citrulline by L-glutamine in endothelial cells. Am J Physio.1993 ;265:H1965 -H1971.

27.

Gao C, Guo H, Wei J, Mi Z, Wai PY, Kuo PC. Identification of S-nitrosylated proteins in endotoxin-stimulated RAW 264.7 murine macrophages.Nitric Oxide . 2005;12:121 -126.

28.

Kim JB, Han AR, Park EY. Inhibition of LPS-induced iNOS, COX-2 and cytokine expression by ponicrin through the NF-kappaB inactivation in RAW 264.7 macrophage cells. Biol Pharm Bull. 2007;30 : 2345-2351.

29.

Wang WW, Jenkinson CP, Griscavage JM, et al. Coinduction of arginase and nitric oxide synthase in murinse macrophage activated by lipopolysaccharide. Biochem Biophys Res Commun.1995 ;210(3):1009 -1016.

30.

Chaturvedi R, Asim M, Lewis ND, et al. L-arginine availability regulates inducible nitric oxide synthase–dependent host defense against Helicobacter pylori. Infect Immun.2007 ;75:4305 -4315.

31.

Bogle R G, Baydoun AR, Pearson JD, Moncada S, Mann GE. L-Arginine transport is increased in macrophages generating nitric oxide. Biochem J. 1992;284:15 -18.

32.

Bode-Böger SM, Muke J, Surdacki A, Brabant G, Böger RH, Frölich JC. Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med.2003 ;8:77 -81.

33.

Piatti PM, Monti LD, Valsecchi G, et al. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care.2001 ;24:875 -880.

34.

Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. J Nutr.2004 ;134:2842S -2847S.

35.

Lee J, Ryu H, Ferrante RJ, Morris SM Jr, Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci.2003 ;100:4843 -4848.

36.

Hammermann R, Bliesener N, Mössner J, et al. Inability of rat alveolar macrophages to recycle L-citrulline to L-arginine despite induction of argininosuccinate synthetase mRNA and protein, and inhibition of nitric oxide synthesis by exogenous L-citrulline. Naunyn Schmiedebergs Arch Pharmaol. 1998;358:601 -607.

37.

Bansal V, Syres KM, Makarenkova V, et al. Interactions between fatty acids and arginine metabolism: implications for the design of immune-enhancing diets. JPEN J Parenter Enteral Nutr.2005 ; 29:S75 -S80.

38.

Ochoa JB, Makarenkova V, Bansal V. A rational use of immune enhancing diets: when should we use dietary arginine supplementation?Nutr Clin Pract . 2004;19:216 -225.

39.

Luiking YC, Poeze M, Ramsay G, Deutz NE. The role of arginine in infection and sepsis. JPEN J Parenter Enteral Nutr.2005 ;29:S70 -S74.

40.

Luiking YC, Deutz NE. Exogenous arginine in sepsis. Crit Care Med. 2007;35(9 suppl): S557-S563.

41.

Moinard C, Cynober L. Citrulline: a new player in the control of nitrogen homeostasis. J Nutr.2007 ;137(6 suppl 2):1621S -1625S.

42.

Waugh WH, Daeschner CW 3rd, Files BA, McConnell ME, Strandjord SE. Oral citrulline as arginine precursor may be beneficial in sickle cell disease: early phase 2 results. J Natl Med Assoc.2001 ;93:363 -371.

43.

Oskowska S, Neveux N, Cynober L, Moinard C. Parenterally administered citrulline increases intestinal adaption following massive intestinal resection. Clin Nutr.2005 ;24:573 -574.

44.

Goeters C, Wenn A, Mertes N, et al. Parenteral L-alanyl-L-glutamine improves 6-month outcome in critically ill patients. Crit Care Med. 2002;30:2032 -2037.

45.

Novak F, Heyland DK, Avenell A, et al. Glutamine supplementation in serious illness: a systematic review of the evidence. Crit Care Med. 2002;30:2022 -2029.

46.

Dechelotte P, Hasselmann M, Cynober L, et al. L-alanyl-L-glutamine dipeptide-supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: the French controlled, randomized, double-blind, multi-center study. Crit Care Med. 2006;34:598 -604.

47.

Houdijk AP, Nijveldt RJ, van Leeuwen PA. Glutamine-enriched enteral feeding in trauma patients: reduced infectious morbidity is not related to changes in endocrine and metabolic responses. JPEN J Parenter Enteral Nutr. 1999;23(5 suppl): S52-S58.